Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiogenesis inhibition in solid tumors.

L S Rosen1

  • 1University of California Los Angeles, 90095, USA.

Cancer Journal (Sudbury, Mass.)
|January 10, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-in-human phase I study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of PF-07209960 in patients with advanced or metastatic solid tumors.

ESMO open·2025
Same author

PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors.

ESMO open·2024
Same author

Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer.

Journal of clinical pharmacy and therapeutics·2014
Same author

A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil.

Anticancer research·2011
Same author

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same author

Plausible models of the sickle hemoglobin fiber based on x-ray diffraction data.

Biophysical journal·2009
Same journal

Present and Emerging Strategies for Disease Assessment in Hodgkin Lymphoma.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Nodular Lymphocyte-predominant Hodgkin Lymphoma: Incidence, Pathogenesis, Management.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Management of Classic Hodgkin Lymphoma in Special Clinical Situations.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Older Patients With Hodgkin Lymphoma: A Contemporary Review.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Adolescent and Young Adult Patients With Classical Hodgkin Lymphoma: A Review as a Case Study in AYA Cancer Care.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Hodgkin Lymphoma: Management of Patients Who Fail Primary Therapy.

Cancer journal (Sudbury, Mass.)·2026
See all related articles

Targeting tumor angiogenesis, the process of new blood vessel growth, is a promising cancer treatment strategy. Inhibiting key factors like vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 shows potential for improving patient survival.

Area of Science:

  • Oncology and Molecular Biology
  • Cancer Research and Therapeutics

Background:

  • Angiogenesis is crucial for tumor growth and metastasis, making it a key target for anti-cancer therapies.
  • Vascular Endothelial Growth Factor (VEGF) and its receptor VEGFR-2 are critical regulators of both normal and neoplastic angiogenesis.

Purpose of the Study:

  • To investigate the therapeutic potential of inhibiting tumor-induced angiogenesis.
  • To evaluate anti-VEGF monoclonal antibodies and VEGFR-2 antagonists in clinical trials for various cancers.
  • To explore the combination of angiogenesis inhibitors with conventional chemotherapy for enhanced anti-tumor activity.

Main Methods:

  • Initiation of clinical trials in 1997 to assess anti-VEGF antibody and VEGFR-2 antagonist efficacy.
  • Dose selection based on preclinical models to achieve optimal biological doses for chronic administration.

Related Experiment Videos

  • Investigating combination therapies of angiogenesis inhibitors with cytotoxic chemotherapy.

    • Main Results:

    • SU5416, a small-molecule VEGFR-2 inhibitor, is well-tolerated and achieves effective concentrations for inhibiting endothelial cell proliferation.
    • Favorable results from Phase 1 and 2 studies indicate the potential of angiogenesis inhibitors.
    • Ongoing randomized, multicenter clinical investigations are evaluating these agents.

    Conclusions:

    • Pharmacologic inhibition of tumor angiogenesis is a promising antineoplastic strategy.
    • VEGF and VEGFR-2 targeted therapies are under active clinical investigation.
    • Combination therapy with chemotherapy may improve cancer patient survival and quality of life.